USD
+$0.00
(+0.00%
)At Close (As of Nov 7, 2025)
$83.33M
Market Cap
-
P/E Ratio
-0.84
EPS
$2.81
52 Week High
$0.71
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | -$3.2M |
| Total Revenue | $166K |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$53M |
| Selling General And Administrative | $15M |
| Research And Development | $35M |
| Operating Expenses | $50M |
| Investment Income Net | - |
| Net Interest Income | $3.3M |
| Interest Income | $3.2M |
| Interest Expense | $22K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $485K |
| Income Before Tax | -$46M |
| Income Tax Expense | $5.2K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$46M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$46M |
| Ebitda | -$46M |
| Net Income | -$46M |
| Field | Value (EUR) |
|---|---|
| Total Assets | $76M |
| Total Current Assets | $72M |
| Cash And Cash Equivalents At Carrying Value | $18M |
| Cash And Short Term Investments | $18M |
| Inventory | $6.9M |
| Current Net Receivables | $1.7M |
| Total Non Current Assets | $4.4M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $51K |
| Intangible Assets Excluding Goodwill | $51K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $3.1M |
| Short Term Investments | $34M |
| Other Current Assets | $10M |
| Other Non Current Assets | - |
| Total Liabilities | $15M |
| Total Current Liabilities | $14M |
| Current Accounts Payable | $11M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $406K |
| Total Non Current Liabilities | $436K |
| Capital Lease Obligations | $805K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $805K |
| Other Current Liabilities | $2.4M |
| Other Non Current Liabilities | $37K |
| Total Shareholder Equity | $61M |
| Treasury Stock | - |
| Retained Earnings | -$332M |
| Common Stock | $7.1M |
| Common Stock Shares Outstanding | $59M |
| Field | Value (EUR) |
|---|---|
| Operating Cashflow | -$49M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $485K |
| Capital Expenditures | $47K |
| Change In Receivables | - |
| Change In Inventory | $4.5M |
| Profit Loss | - |
| Cashflow From Investment | $52M |
| Cashflow From Financing | $386K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$46M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | -$3.2M |
| Total Revenue | $166K |
| Cost Of Revenue | $3.3M |
| Costof Goods And Services Sold | $3.3M |
| Operating Income | -$53M |
| Selling General And Administrative | $15M |
| Research And Development | $35M |
| Operating Expenses | $50M |
| Investment Income Net | - |
| Net Interest Income | $3.3M |
| Interest Income | $3.2M |
| Interest Expense | $22K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $485K |
| Income Before Tax | -$46M |
| Income Tax Expense | $5.2K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$46M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$46M |
| Ebitda | -$46M |
| Net Income | -$46M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
InflaRx N.V. is a clinical-stage biopharmaceutical company focused on the development of novel C5a inhibitors targeting the complement system for the treatment of serious inflammatory and autoimmune diseases. Headquartered in Jena, Germany, with a strategic presence in the United States, the company is advancing its innovative therapeutic pipeline led by its candidate IFX-1, currently under evaluation for hidradenitis suppurativa and other indications. InflaRx's commitment to addressing unmet medical needs, combined with its pioneering research, positions it as a key player in the biopharmaceutical industry with potential for substantial impact in the treatment landscape.